145 related articles for article (PubMed ID: 34527642)
1. A
Zhao W; Hu X; Liu Y; Wang X; Chen Y; Wang Y; Zhou H
Front Pediatr; 2021; 9():678615. PubMed ID: 34527642
[TBL] [Abstract][Full Text] [Related]
2. Screening of CD96 and ASXL1 in 11 patients with Opitz C or Bohring-Opitz syndromes.
Urreizti R; Roca-Ayats N; Trepat J; Garcia-Garcia F; Aleman A; Orteschi D; Marangi G; Neri G; Opitz JM; Dopazo J; Cormand B; Vilageliu L; Balcells S; Grinberg D
Am J Med Genet A; 2016 Jan; 170A(1):24-31. PubMed ID: 26768331
[TBL] [Abstract][Full Text] [Related]
3. Bohring-Opitz syndrome caused by an ASXL1 mutation inherited from a germline mosaic mother.
Bedoukian E; Copenheaver D; Bale S; Deardorff M
Am J Med Genet A; 2018 May; 176(5):1249-1252. PubMed ID: 29681100
[TBL] [Abstract][Full Text] [Related]
4. Bohring-Opitz syndrome (BOS) with a new ASXL1 pathogenic variant: Review of the most prevalent molecular and phenotypic features of the syndrome.
Dangiolo SB; Wilson A; Jobanputra V; Anyane-Yeboa K
Am J Med Genet A; 2015 Dec; 167A(12):3161-6. PubMed ID: 26364555
[TBL] [Abstract][Full Text] [Related]
5. Novel truncating mutations in ASXL1 identified in two boys with Bohring-Opitz syndrome.
Zhao J; Hou Y; Fang F; Ding C; Yang X; Li J; Cui D; Cao Z; Zhang H
Eur J Med Genet; 2021 Mar; 64(3):104155. PubMed ID: 33529703
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.
Russell B; Johnston JJ; Biesecker LG; Kramer N; Pickart A; Rhead W; Tan WH; Brownstein CA; Kate Clarkson L; Dobson A; Rosenberg AZ; Vergano SA; Helm BM; Harrison RE; Graham JM
Am J Med Genet A; 2015 Sep; 167A(9):2122-31. PubMed ID: 25921057
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome.
Carlston CM; O'Donnell-Luria AH; Underhill HR; Cummings BB; Weisburd B; Minikel EV; Birnbaum DP; ; Tvrdik T; MacArthur DG; Mao R
Hum Mutat; 2017 May; 38(5):517-523. PubMed ID: 28229513
[TBL] [Abstract][Full Text] [Related]
8. Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation.
Lin I; Wei A; Awamleh Z; Singh M; Ning A; Herrera A; ; Russell BE; Weksberg R; Arboleda VA
JCI Insight; 2023 May; 8(10):. PubMed ID: 37053013
[TBL] [Abstract][Full Text] [Related]
9. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome.
Bainbridge MN; Hu H; Muzny DM; Musante L; Lupski JR; Graham BH; Chen W; Gripp KW; Jenny K; Wienker TF; Yang Y; Sutton VR; Gibbs RA; Ropers HH
Genome Med; 2013; 5(2):11. PubMed ID: 23383720
[TBL] [Abstract][Full Text] [Related]
10. A
Efthymiou S; Salpietro V; Pironti E; Bonsignore M; Ferrazzoli V; Rosa GD; Houlden H
J Genet; 2019 Dec; 98():. PubMed ID: 31819025
[TBL] [Abstract][Full Text] [Related]
11. Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations.
Magini P; Della Monica M; Uzielli ML; Mongelli P; Scarselli G; Gambineri E; Scarano G; Seri M
Am J Med Genet A; 2012 Apr; 158A(4):917-21. PubMed ID: 22419483
[TBL] [Abstract][Full Text] [Related]
12. Extending the phenotypic spectrum of Bohring-Opitz syndrome: Mild case confirmed by functional studies.
Leon E; Diaz J; Castilla-Vallmanya L; Grinberg D; Balcells S; Urreizti R
Am J Med Genet A; 2020 Jan; 182(1):201-204. PubMed ID: 31692235
[TBL] [Abstract][Full Text] [Related]
13. Expanding the clinical spectrum of recessive truncating mutations of
Bruel AL; Bigoni S; Kennedy J; Whiteford M; Buxton C; Parmeggiani G; Wherlock M; Woodward G; Greenslade M; Williams M; St-Onge J; Ferlini A; Garani G; Ballardini E; van Bon BW; Acuna-Hidalgo R; Bohring A; Deleuze JF; Boland A; Meyer V; Olaso R; Ginglinger E; Study D; Rivière JB; Brunner HG; Hoischen A; Newbury-Ecob R; Faivre L; Thauvin-Robinet C; Thevenon J
J Med Genet; 2017 Dec; 54(12):830-835. PubMed ID: 29074562
[TBL] [Abstract][Full Text] [Related]
14. Lethal persistent pulmonary hypertension of the newborn in Bohring-Opitz syndrome.
Kibe M; Ibara S; Inagaki H; Kato T; Kurahashi H; Ikeda T
Am J Med Genet A; 2018 May; 176(5):1245-1248. PubMed ID: 29681105
[TBL] [Abstract][Full Text] [Related]
15. Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition.
Kuechler A; Czeschik JC; Graf E; Grasshoff U; Hüffmeier U; Busa T; Beck-Woedl S; Faivre L; Rivière JB; Bader I; Koch J; Reis A; Hehr U; Rittinger O; Sperl W; Haack TB; Wieland T; Engels H; Prokisch H; Strom TM; Lüdecke HJ; Wieczorek D
Eur J Hum Genet; 2017 Feb; 25(2):183-191. PubMed ID: 27901041
[TBL] [Abstract][Full Text] [Related]
16. De Novo Truncating Variants in ASXL2 Are Associated with a Unique and Recognizable Clinical Phenotype.
Shashi V; Pena LD; Kim K; Burton B; Hempel M; Schoch K; Walkiewicz M; McLaughlin HM; Cho M; Stong N; Hickey SE; Shuss CM; ; Freemark MS; Bellet JS; Keels MA; Bonner MJ; El-Dairi M; Butler M; Kranz PG; Stumpel CT; Klinkenberg S; Oberndorff K; Alawi M; Santer R; Petrovski S; Kuismin O; Korpi-Heikkilä S; Pietilainen O; Aarno P; Kurki MI; Hoischen A; Need AC; Goldstein DB; Kortüm F
Am J Hum Genet; 2016 Oct; 99(4):991-999. PubMed ID: 27693232
[TBL] [Abstract][Full Text] [Related]
17. Bohring-Opitz syndrome caused by a novel ASXL1 mutation (c.3762delT) in an IVF baby: A case report.
Wang D; Yuan X; Guo H; Yan S; Wang G; Wang Y; Wang T; He J; Peng X
Medicine (Baltimore); 2022 Feb; 101(5):e28759. PubMed ID: 35119035
[TBL] [Abstract][Full Text] [Related]
18. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.
Hoischen A; van Bon BW; Rodríguez-Santiago B; Gilissen C; Vissers LE; de Vries P; Janssen I; van Lier B; Hastings R; Smithson SF; Newbury-Ecob R; Kjaergaard S; Goodship J; McGowan R; Bartholdi D; Rauch A; Peippo M; Cobben JM; Wieczorek D; Gillessen-Kaesbach G; Veltman JA; Brunner HG; de Vries BB
Nat Genet; 2011 Jun; 43(8):729-31. PubMed ID: 21706002
[TBL] [Abstract][Full Text] [Related]
19. Clinical findings in 39 individuals with Bohring-Opitz syndrome from a global patient-driven registry with implications for tumor surveillance and recurrence risk.
Russell BE; Kianmahd RR; Munster C; Yu A; Ahad L; Tan WH
Am J Med Genet A; 2023 Apr; 191(4):1050-1058. PubMed ID: 36751885
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
